| 9682978 |
2,6,7 substituted purines as HDM2 inhibitors |
Matthew Christopher, Francesc Xavier Fradera Llinas, Michelle R. Machacek, Michelle Martinez, Michael H. Reutershan +5 more |
2017-06-20 |
$284,541,000 |
| 9637493 |
Substituted pyrrolopyrimidines as HDM2 inhibitors |
Christopher J. Dinsmore, Francesc Xavier Fradera Llinas, Amit Ashokro Kudale, Michelle R. Machacek, Michael H. Reutershan +6 more |
2017-05-02 |
$258,821,000 |
| 9540377 |
2,6,7,8 substituted purines as HDM2 inhibitors |
Carolyn Michele Cammarano, Matthew Christopher, Christopher J. Dinsmore, Ronald J. Doll, Francesc Xavier Fradera Llinas +16 more |
2017-01-10 |
$109,765,000 |
| 9062071 |
Substituted piperidines as HDM2 inhibitors |
Yao-Dong Ma, Manami Shizuka, Timothy J. Guzi, Yuan Liu, Yuan Tian +10 more |
2015-06-23 |
$67,157,000 |
| 8980916 |
Factor IXa inhibitors |
Hiroki Sone, Samuel Chackalamannil, Munetaka Ohkouchi |
2015-03-17 |
$59,557,000 |
| 8962611 |
Substituted imidazopyridines as HDM2 inhibitors |
Matthew Christopher, Francesc Xavier Fradera Llinas, Michelle R. Machacek, Michelle Martinez, Michael H. Reutershan +7 more |
2015-02-24 |
$132,352,000 |
| 8895543 |
Vinca derivatives |
Ian L. Scott, Jeffrey M. Ralph |
2014-11-25 |
$5,909,000 |
| 8859776 |
Substituted piperidines that increase p53 activity and the uses thereof |
Stephane L. Bogen, Yao-Dong Ma, Yaolin Wang, Brian Robert Lahue, Latha G. Nair +15 more |
2014-10-14 |
$39,553,000 |
| 8846657 |
Substituted imidazopyridines as HDM2 inhibitors |
Matthew Christopher, Francesc Xavier Fradera Llinas, Michelle R. Machacek, Michelle Martinez, Michael H. Reutershan +7 more |
2014-09-30 |
$59,576,000 |
| 8222421 |
Certain substituted ureas, as modulators of kinase activity |
Scott A. Mitchell, Mihaela Diana Danca, Peter A. Blomgren, David R. Brittelli, Pavel E. Zhichkin |
2012-07-17 |
|
| 8053428 |
Vinorelbine derivatives |
Ian L. Scott, Jeffrey M. Ralph |
2011-11-08 |
$873,000 |
| 7884107 |
Substituted piperidines that increase P53 activity and the uses thereof |
Yao-Dong Ma, Brian Robert Lahue, Gerald W. Shipps, Jr., Yaolin Wang, Stephane L. Bogen +10 more |
2011-02-08 |
$84,886,000 |
| 7842802 |
Vinorelbine derivatives |
Ian L. Scott, Jeffrey M. Ralph |
2010-11-30 |
$1,270,000 |
| 7777040 |
Certain substituted ureas, as modulators of kinase activity |
Scott A. Mitchell, Mihaela Diana Danca, Peter A. Blomgren, David R. Brittelli, Pavel E. Zhichkin |
2010-08-17 |
$7,805,000 |
| 7745619 |
Vinca derivatives |
Ian L. Scott, Jeffrey M. Ralph |
2010-06-29 |
$1,500,000 |
| 7338975 |
Lactams as modulators of chemokine receptor activity |
Percy H. Carter |
2008-03-04 |
$33,354,000 |
| 7238704 |
Vinca derivatives |
Ian L. Scott, Jeffrey M. Ralph |
2007-07-03 |
|
| 7235564 |
Vinorelbine derivatives |
Ian L. Scott, Jeffrey M. Ralph |
2007-06-26 |
|
| 6984648 |
Cyclic β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α |
Zhonghui Lu, Thomas P. Maduskuie, Jr., Chu-Biao Xue, Jingwu Duan, Gregory R. Ott +2 more |
2006-01-10 |
$47,832,000 |
| 6962938 |
Spiro-cyclic β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α converting enzyme (TACE) |
Gregory R. Ott, Xiao-Tao Chen, Jingwu Duan |
2005-11-08 |
$36,734,000 |
| 6884806 |
Bicyclic lactam derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) |
Carl P. Decicco, Ying Song, Jingwu Duan |
2005-04-26 |
$49,727,000 |
| 6720329 |
Spiro-cyclic &bgr;-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-&agr; converting enzyme (TACE) |
Gregory R. Ott, Xiao-Tao Chen, Jingwu Duan |
2004-04-13 |
$81,274,000 |
| 6495565 |
&bgr;-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-&agr; |
Jingwu Duan, Bryan Wayne King, Carl P. Decicco, Thomas P. Maduskuie, Jr. |
2002-12-17 |
$110,945,000 |
| 6455522 |
Cyclic sulfonamide derivatives as metalloproteinase inhibitors |
Jingwu Duan, Lihua Chen, Robert J. Cherney, Carl P. Decicco |
2002-09-24 |
$77,861,000 |
| 6365587 |
Substituted aryl hydroxamic acids as metalloproteinase inhibitors |
Carl P. Decicco, Ruth R. Wexler |
2002-04-02 |
|
